Eosinophilic Esophagitis: Novel Therapeutic Developments and Impact on...

Actions Panel

Eosinophilic Esophagitis: Novel Therapeutic Developments and Impact on...

Join in-person or virtually!

When and where

Date and time

Location

The Westin Charlotte 601 South College Street Grand Ballroom C; Level 2 Charlotte, NC 28202

Map and directions

How to get there

About this event

Activity Chair

Evan S. Dellon, MD, MPH

Professor

Division of Gastroenterology and Hepatology

Dept of Medicine

University of North Carolina School of Medicine

Chapel Hill, NC

Faculty

Claire Beveridge, MD

Associate Staff

Department of Gastroenterology, Hepatology & Nutrition

Cleveland Clinic

Assistant Professor of Medicine

Cleveland Clinic Lerner College of Medicine

Case Western Reserve University

Cleveland, OH

Mirna Chehade, MD, MPH

Professor of Pediatrics and Medicine

Director, Mount Sinai Center for Eosinophilic Disorders

Icahn School of Medicine at Mount Sinai

New York, NY

Ikuo Hirano, MD

Professor of Medicine

Northwestern University Feinberg School of Medicine

Chicago, IL

Overview

Eosinophilic esophagitis (EoE) is a chronic type 2 helper (Th2)-mediated inflammatory disorder that affects both children and adults. It is characterized by symptoms of esophageal dysfunction and esophageal inflammation with intraepithelial eosinophils. Once considered rare, EoE is a relatively new disease that is now commonplace. When left unmanaged, EoE can impact a patient’s ability to eat properly, leading to food impaction and increased medical expenses. Real-world data indicate that many patients with EoE switch therapy frequently, demonstrating an unmet need for adequate control of disease-related symptoms. Many gastroenterologists and other relevant providers lack an understanding of the pathogenesis, guideline-based diagnostic criteria, and newly approved and emerging treatment options for EoE. These knowledge deficits may therefore exacerbate delays in diagnoses and, consequently, appropriate management. In this educational program, expert clinicians will review the pathogenesis and best practices for accurate diagnosis of EoE. They will also explore current treatment guidelines and the clinical data supporting the use of recently approved and emerging therapies for EoE. Interactive case discussions are included to challenge the audience’s ability to apply the learnings from the didactic presentations.

Agenda

5:30 PM

Registration and Dinner

6:00 PM

Introduction and Pretest

Evan S. Dellon, MD, MPH

6:05 PM

Pathogenesis of EoE

Claire Beveridge, MD

6:20 PM

EoE Diagnosis: Advances and Challenges

Mirna Chehade, MD, MPH

6:40 PM

Case Presentation and Panel Discussion

Evan S. Dellon, MD, MPH

6:50 PM

Treatment of EoE: Novel and Emerging Therapies

Ikuo Hirano, MD

7:05 PM

Case Presentation and Panel Discussion

Evan S. Dellon, MD, MPH

7:20 PM

Posttest and Question & Answer

7:30 PM

Conclusion

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Identify the latest findings on the pathogenesis of EoE.

  • Summarize the criteria for diagnosis of EoE and tools to detect the condition.

  • Outline the clinical evidence for current, newly approved, and emerging therapies for EoE including the latest guideline recommendations.

Target Audience

The intended audience for this activity is gastroenterologists and other health care professionals involved in the management of patients with EoE.

This continuing medical education activity is provided by Vindico Medical Education.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

This event is neither sponsored by nor endorsed by ACG.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will be mitigated prior to the commencement of the activity.

Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.